| Identification | Back Directory | [Name]
L-Phenylalaninamide, L-tyrosyl-L-prolyl-L-tryptophyl-, acetate (1:1) | [CAS]
1276123-71-7 | [Synonyms]
Endomorphin 1 acetate
L-Phenylalaninamide, L-tyrosyl-L-prolyl-L-tryptophyl-, acetate (1:1) | [Molecular Formula]
C36H42N6O7 | [MOL File]
1276123-71-7.mol | [Molecular Weight]
670.77 |
| Hazard Information | Back Directory | [Uses]
Endomorphin 1 acetate, a high affinity, highly selective agonist of the μ-opioid receptor (Ki: 1.11 nM), displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM. Endomorphin 1 acetate has antinociceptive properties[1][2][4]. | [in vivo]
Endomorphin 1 (i.c.v.) acetate shows antinociceptive properties in mice, with an ED50 value of 6.16 nM[2].
Endomorphin 1 (50 μg/kg, i.v., rats) acetate alleviates myocardial ischemia/reperfusion injury (MIRI) by inhibiting the inflammatory response[3].
| Animal Model: | ICR mice[2]. | | Dosage: | 6.16 nM (ED50) | | Administration: | Intracerebroventricularly (i.c.v.) injection | | Result: | Inhibited dose-dependently the tail-flick response. |
| Animal Model: | Rats[3].
| | Dosage: | 50 μg/kg | | Administration: | Intravenously following LAD ligation for 25 min, subsequently the LAD was reperfused for 120 min. | | Result: | Alleviated MIRI by reducing the production of free radicals.
Dncreased LDH and CK-MB activities.
Increased SOD activity and decreased MDA content.
Decreased IL-6 and TNF-α plasma content.
|
| [IC 50]
μ Opioid Receptor/MOR: 1.11 nM (Ki) | [References]
[1] Goldberg IE, et al. Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. J Pharmacol Exp Ther. 1998 Aug;286(2):1007-13. PMID:9694962
[2] Tseng LF. The antinociceptive properties of endomorphin-1 and endomorphin-2 in the mouse. Jpn J Pharmacol. 2002 Jul;89(3):216-20. DOI:10.1254/jjp.89.216
[3] Zhang WP, et al. Effects of endomorphin-1 postconditioning on myocardial ischemia/reperfusion injury and myocardial cell apoptosis in a rat model. Mol Med Rep. 2016 Oct;14(4):3992-8. DOI:10.3892/mmr.2016.5695
[4] Koda Y, et al. Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg Med Chem. 2008 Jun 1;16(11):6286-96. DOI:10.1016/j.bmc.2008.04.020
[5] Harrison C, et al. The effects of endomorphin-1 and endomorphin-2 in CHO cells expressing recombinant mu-opioid receptors and SH-SY5Y cells. Br J Pharmacol. 1999 Sep;128(2):472-8. DOI:10.1038/sj.bjp.0702798
[6] Neudeck BL, et al. Endomorphin-1 alters interleukin-8 secretion in Caco-2 cells via a receptor mediated process. Immunol Lett. 2002 Dec 3;84(3):217-21. DOI:10.1016/s0165-2478(02)00198-0
[7] Fujita T, et al. Inhibition by endomorphin-1 and endomorphin-2 of excitatory transmission in adult rat substantia gelatinosa neurons. Neuroscience. 2006;139(3):1095-105. DOI:10.1016/j.neuroscience.2006.01.010 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
www.biorbyt.com |
|